当前位置:
X-MOL 学术
›
Nat. Commun.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Nature Communications ( IF 14.7 ) Pub Date : 2021-05-05 , DOI: 10.1038/s41467-021-23082-3 Sho Iketani , Farhad Forouhar , Hengrui Liu , Seo Jung Hong , Fang-Yu Lin , Manoj S. Nair , Arie Zask , Yaoxing Huang , Li Xing , Brent R. Stockwell , Alejandro Chavez , David D. Ho
Nature Communications ( IF 14.7 ) Pub Date : 2021-05-05 , DOI: 10.1038/s41467-021-23082-3 Sho Iketani , Farhad Forouhar , Hengrui Liu , Seo Jung Hong , Fang-Yu Lin , Manoj S. Nair , Arie Zask , Yaoxing Huang , Li Xing , Brent R. Stockwell , Alejandro Chavez , David D. Ho
A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-23082-3
中文翻译:
作者更正:用于开发SARS-CoV-2 3CL蛋白酶抑制剂的主要化合物
已发布对本文的更正:https://doi.org/10.1038/s41467-021-23082-3
更新日期:2021-05-06
中文翻译:
作者更正:用于开发SARS-CoV-2 3CL蛋白酶抑制剂的主要化合物
已发布对本文的更正:https://doi.org/10.1038/s41467-021-23082-3